<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" returnVersion="2023v5.0">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2024-05-14T07:54:39-04:00</ReturnTs>
    <TaxPeriodEndDt>2023-12-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>382463166</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>ALAN C YOUNG &amp; ASSOCIATES PC</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>7310 WOODWARD AVE STE 740</AddressLine1Txt>
        <CityNm>DETROIT</CityNm>
        <StateAbbreviationCd>MI</StateAbbreviationCd>
        <ZIPCd>48202</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990</ReturnTypeCd>
    <TaxPeriodBeginDt>2023-01-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>270097769</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>EICOSANOID RESEARCH FOUNDATION</BusinessNameLine1Txt>
        <BusinessNameLine2Txt>C/O KRISHNARAO MADDIPATI</BusinessNameLine2Txt>
      </BusinessName>
      <BusinessNameControlTxt>EICO</BusinessNameControlTxt>
      <PhoneNum>3135772999</PhoneNum>
      <USAddress>
        <AddressLine1Txt>5101 CASS AVENUE 435 CHEMISTRY BLD</AddressLine1Txt>
        <CityNm>DETROIT</CityNm>
        <StateAbbreviationCd>MI</StateAbbreviationCd>
        <ZIPCd>48202</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>CHARLES SERHAN</PersonNm>
      <PersonTitleTxt>PRESIDENT</PersonTitleTxt>
      <PhoneNum>3135772999</PhoneNum>
      <SignatureDt>2024-05-08</SignatureDt>
      <DiscussWithPaidPreparerInd>true</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <SigningOfficerGrp>
      <PersonFullName>
        <PersonFirstNm>CHARLES</PersonFirstNm>
        <PersonLastNm>SERHAN</PersonLastNm>
      </PersonFullName>
      <SSN>999009999</SSN>
    </SigningOfficerGrp>
    <IRSResponsiblePrtyInfoCurrInd>false</IRSResponsiblePrtyInfoCurrInd>
    <PreparerPersonGrp>
      <PreparerPersonNm>ALAN C YOUNG</PreparerPersonNm>
      <PTIN>P00138984</PTIN>
      <PhoneNum>3138737500</PhoneNum>
      <PreparationDt>2024-05-13</PreparationDt>
    </PreparerPersonGrp>
    <TaxYr>2023</TaxYr>
    <BuildTS>2023-04-26 12:10:37Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="3">
    <IRS990 documentId="RetDoc1" referenceDocumentId="RetDoc2">
      <PrincipalOfficerNm>CHARLES SERHAN</PrincipalOfficerNm>
      <USAddress>
        <AddressLine1Txt>5101 CASS AVENUE 431 CHEMISTRY BLD</AddressLine1Txt>
        <CityNm>DETROIT</CityNm>
        <StateAbbreviationCd>MI</StateAbbreviationCd>
        <ZIPCd>48202</ZIPCd>
      </USAddress>
      <GrossReceiptsAmt>20080</GrossReceiptsAmt>
      <GroupReturnForAffiliatesInd>false</GroupReturnForAffiliatesInd>
      <Organization501c3Ind>X</Organization501c3Ind>
      <WebsiteAddressTxt>WWW.EICOSANOIDRESEARCHFOUNDATION.ORG</WebsiteAddressTxt>
      <TypeOfOrganizationCorpInd>X</TypeOfOrganizationCorpInd>
      <FormationYr>2004</FormationYr>
      <ActivityOrMissionDesc>THE PRIMARY EXEMPT PURPOSE OF THE EICOSANOID RESEARCH FOUNDATION IS TO PROVIDE A FORUM FOR THE DISSEMINATION OF THE LATEST SCIENTIFIC INFORMATION ON BIOACTIVE LIPIDS IN HEALTH AND DISEASE AS IT RELATES TO CANCER, INFLAMATION AND INFLAMATION INDUCED DISEASES SUCH AS CARDIOVASCULAR, DIABETES, PSORIASIS AND ALZHEIMER'S. THIS PURPOSE IS ACCOMPLISHED THROUGH THE ORGANIZATION'S BIENNIAL CONFERENCE. THE EICOSANOID RESEARCH FOUNDATION SPONSORS BIENNIAL CONFERENCES HIGHLIGHTING DATA AT THE CUTTING EDGE OF MEDICAL SCIENCE. DURING THESE CONFERENCES NEW DRUGS AND MEDICATIONS ARE DISCUSSED, DATA ON CLINICAL TRIALS IS EXAMINED AND SCIENTISTS FROM ALL OVER THE WORLD INTERACT TO ENHANCE THEIR COLLABORATIVE RESEARCH EFFORTS. THE GOAL OF THIS MEETING SERIES IS TO PROMOTE THE EXCHANGE OF INFORMATION AND IDEAS AMONG INTERNATIONAL SCIENTISTS OF DIVERSE BACKGROUNDS. THE MAIN PURPOSE OF THE EICOSANOID RESEARCH FOUNDATION IS TO RAISE FUNDS TO SPONSOR THE INTERNATIONAL CONFERENCE ON BIOACTIVE LIPIDS IN CANCER,</ActivityOrMissionDesc>
      <VotingMembersGoverningBodyCnt>6</VotingMembersGoverningBodyCnt>
      <VotingMembersIndependentCnt>6</VotingMembersIndependentCnt>
      <TotalEmployeeCnt>0</TotalEmployeeCnt>
      <TotalGrossUBIAmt>0</TotalGrossUBIAmt>
      <PYContributionsGrantsAmt>139190</PYContributionsGrantsAmt>
      <CYContributionsGrantsAmt>18956</CYContributionsGrantsAmt>
      <PYProgramServiceRevenueAmt>126541</PYProgramServiceRevenueAmt>
      <CYProgramServiceRevenueAmt>0</CYProgramServiceRevenueAmt>
      <PYInvestmentIncomeAmt>17</PYInvestmentIncomeAmt>
      <CYInvestmentIncomeAmt>2</CYInvestmentIncomeAmt>
      <CYOtherRevenueAmt>1122</CYOtherRevenueAmt>
      <PYTotalRevenueAmt>265748</PYTotalRevenueAmt>
      <CYTotalRevenueAmt>20080</CYTotalRevenueAmt>
      <CYGrantsAndSimilarPaidAmt>0</CYGrantsAndSimilarPaidAmt>
      <CYBenefitsPaidToMembersAmt>0</CYBenefitsPaidToMembersAmt>
      <CYSalariesCompEmpBnftPaidAmt>0</CYSalariesCompEmpBnftPaidAmt>
      <CYTotalProfFndrsngExpnsAmt>0</CYTotalProfFndrsngExpnsAmt>
      <CYTotalFundraisingExpenseAmt>0</CYTotalFundraisingExpenseAmt>
      <PYOtherExpensesAmt>332097</PYOtherExpensesAmt>
      <CYOtherExpensesAmt>26426</CYOtherExpensesAmt>
      <PYTotalExpensesAmt>332097</PYTotalExpensesAmt>
      <CYTotalExpensesAmt>26426</CYTotalExpensesAmt>
      <PYRevenuesLessExpensesAmt>-66349</PYRevenuesLessExpensesAmt>
      <CYRevenuesLessExpensesAmt>-6346</CYRevenuesLessExpensesAmt>
      <TotalAssetsBOYAmt>17889</TotalAssetsBOYAmt>
      <TotalAssetsEOYAmt>10801</TotalAssetsEOYAmt>
      <TotalLiabilitiesEOYAmt>-742</TotalLiabilitiesEOYAmt>
      <NetAssetsOrFundBalancesBOYAmt>17889</NetAssetsOrFundBalancesBOYAmt>
      <NetAssetsOrFundBalancesEOYAmt>11543</NetAssetsOrFundBalancesEOYAmt>
      <InfoInScheduleOPartIIIInd>X</InfoInScheduleOPartIIIInd>
      <MissionDesc>THE PRIMARY EXEMPT PURPOSE OF THE EICOSANOID RESEARCH FOUNDATION IS TO PROVIDE A FORUM FOR THE DISSEMINATION OF THE LATEST SCIENTIFIC INFORMATION ON BIOACTIVE LIPIDS IN HEALTH AND DISEASE AS IT RELATES TO CANCER, INFLAMATION AND INFLAMATION INDUCED DISEASES SUCH AS CARDIOVASCULAR, DIABETES, PSORIASIS AND ALZHEIMER'S. THIS PURPOSE IS ACCOMPLISHED THROUGH THE ORGANIZATION'S BIENNIAL CONFERENCE. THE EICOSANOID RESEARCH FOUNDATION SPONSORS BIENNIAL CONFERENCES HIGHLIGHTING DATA AT THE CUTTING EDGE OF MEDICAL SCIENCE. DURING THESE CONFERENCES NEW DRUGS AND MEDICATIONS ARE DISCUSSED, DATA ON CLINICAL TRIALS IS EXAMINED AND SCIENTISTS FROM ALL OVER THE WORLD INTERACT TO ENHANCE THEIR COLLABORATIVE RESEARCH EFFORTS. THE GOAL OF THIS MEETING SERIES IS TO PROMOTE THE EXCHANGE OF INFORMATION AND IDEAS AMONG INTERNATIONAL SCIENTISTS OF DIVERSE BACKGROUNDS. THE MAIN PURPOSE OF THE EICOSANOID RESEARCH FOUNDATION IS TO RAISE FUNDS TO SPONSOR THE INTERNATIONAL CONFERENCE ON BIOACTIVE LIPIDS IN CANCER,</MissionDesc>
      <SignificantNewProgramSrvcInd>false</SignificantNewProgramSrvcInd>
      <SignificantChangeInd>false</SignificantChangeInd>
      <ExpenseAmt>25051</ExpenseAmt>
      <Desc>BIENNIAL BIOACTIVE LIPIDS CONFERENCE: THE ORGANIZATION HELD AN INFORMATIVE AND SUCCESSFUL CONFERENCE IN THE FALL OF 2022 RELATING TO THE DISSEMINATION OF THE LATEST SCIENTIFIC AND MEDICAL INFORMATION ON BIO-ACTIVE LIPIDS IN HEALTH AND DISEASE, INCLUDING CANCER. THIS WAS THE 17TH INTERNATIONAL CONFERENCE SCHEDULED IN NEW ORLEANS, LOUISIANA, USA FROM OCTOBER 30 - NOVEMBER 2, 2022. THE CONFERENCE SUCCESSFULLY PROMOTED THE EXCHANGE OF IDEAS AND THEORIES IN THIS AREA AMONG SCIENTISTS AND MEDICAL PROFESSIONALS AROUND THE WORLD, IN AN EFFORT TO FIND A CURE FOR DIEASE AND THE RESOLUTIN OF IMFLAMMATORY DISEASES.</Desc>
      <ProgSrvcAccomActy2Grp>
        <Desc>ANNUAL WAYNE STATE UNIVERSITY LIPIDS SYMPOSIUM: THE WAYNE STATE UNIVERSITY LIPIDS SYMPOSIUM ADDRESSES THE VITAL ROLES OF LIPIDS IN CELLULAR PROCESSES REQUIRED FOR NORMAL PHYSIOLOGICAL FUNCTION. THE 7TH WSU LIPIDS SYMPOSIUM WAS SCHEDULED FOR MAY 13, 2020 IN THE STUDENT BALLROOM ON THE MAIN CAMPUS OF WAYNE STATE UNIVERSITY. DUE TO THE COVID-19 PANDEMIC, THE EVENT WAS CANCELED. THE SYMPOSIUM HAS BEEN SUSPENDED SINCE THAT POINT, BUT IS CURRENTLY EXPECTED TO RESUME IN EITHER 2023 OR 2024. PREVIOUSLY, THE (6TH) WSU LIPIDS SYMPOSIUM WAS HELD IN THE STUDENT CENTER BALLROOM ON THE MAIN CAMPUS OF WAYNE STATE UNIVERSITY ON MAY 7, 2019 AND WAS WELL ATTENDED.</Desc>
      </ProgSrvcAccomActy2Grp>
      <TotalProgramServiceExpensesAmt>25051</TotalProgramServiceExpensesAmt>
      <DescribedInSection501c3Ind referenceDocumentId="RetDoc3">true</DescribedInSection501c3Ind>
      <ScheduleBRequiredInd>false</ScheduleBRequiredInd>
      <PoliticalCampaignActyInd>false</PoliticalCampaignActyInd>
      <LobbyingActivitiesInd>false</LobbyingActivitiesInd>
      <SubjectToProxyTaxInd>false</SubjectToProxyTaxInd>
      <DonorAdvisedFundInd>false</DonorAdvisedFundInd>
      <ConservationEasementsInd>false</ConservationEasementsInd>
      <CollectionsOfArtInd>false</CollectionsOfArtInd>
      <CreditCounselingInd>false</CreditCounselingInd>
      <DonorRstrOrQuasiEndowmentsInd>false</DonorRstrOrQuasiEndowmentsInd>
      <ReportLandBuildingEquipmentInd>false</ReportLandBuildingEquipmentInd>
      <ReportInvestmentsOtherSecInd>false</ReportInvestmentsOtherSecInd>
      <ReportProgramRelatedInvstInd>false</ReportProgramRelatedInvstInd>
      <ReportOtherAssetsInd>false</ReportOtherAssetsInd>
      <ReportOtherLiabilitiesInd>false</ReportOtherLiabilitiesInd>
      <IncludeFIN48FootnoteInd>false</IncludeFIN48FootnoteInd>
      <IndependentAuditFinclStmtInd>false</IndependentAuditFinclStmtInd>
      <ConsolidatedAuditFinclStmtInd>false</ConsolidatedAuditFinclStmtInd>
      <SchoolOperatingInd>false</SchoolOperatingInd>
      <ForeignOfficeInd>false</ForeignOfficeInd>
      <ForeignActivitiesInd>false</ForeignActivitiesInd>
      <MoreThan5000KToOrgInd>false</MoreThan5000KToOrgInd>
      <MoreThan5000KToIndividualsInd>false</MoreThan5000KToIndividualsInd>
      <ProfessionalFundraisingInd>false</ProfessionalFundraisingInd>
      <FundraisingActivitiesInd>false</FundraisingActivitiesInd>
      <GamingActivitiesInd>false</GamingActivitiesInd>
      <OperateHospitalInd>false</OperateHospitalInd>
      <GrantsToOrganizationsInd>false</GrantsToOrganizationsInd>
      <GrantsToIndividualsInd>false</GrantsToIndividualsInd>
      <ScheduleJRequiredInd>false</ScheduleJRequiredInd>
      <TaxExemptBondsInd>false</TaxExemptBondsInd>
      <EngagedInExcessBenefitTransInd>false</EngagedInExcessBenefitTransInd>
      <PYExcessBenefitTransInd>false</PYExcessBenefitTransInd>
      <LoanOutstandingInd>false</LoanOutstandingInd>
      <GrantToRelatedPersonInd>false</GrantToRelatedPersonInd>
      <BusinessRlnWithOrgMemInd>false</BusinessRlnWithOrgMemInd>
      <BusinessRlnWithFamMemInd>false</BusinessRlnWithFamMemInd>
      <BusinessRlnWith35CtrlEntInd>false</BusinessRlnWith35CtrlEntInd>
      <DeductibleNonCashContriInd>false</DeductibleNonCashContriInd>
      <DeductibleArtContributionInd>false</DeductibleArtContributionInd>
      <TerminateOperationsInd>false</TerminateOperationsInd>
      <PartialLiquidationInd>false</PartialLiquidationInd>
      <DisregardedEntityInd>false</DisregardedEntityInd>
      <RelatedEntityInd>false</RelatedEntityInd>
      <RelatedOrganizationCtrlEntInd>false</RelatedOrganizationCtrlEntInd>
      <TrnsfrExmptNonChrtblRltdOrgInd>false</TrnsfrExmptNonChrtblRltdOrgInd>
      <ActivitiesConductedPrtshpInd>false</ActivitiesConductedPrtshpInd>
      <ScheduleORequiredInd>true</ScheduleORequiredInd>
      <IRPDocumentCnt>0</IRPDocumentCnt>
      <IRPDocumentW2GCnt>0</IRPDocumentW2GCnt>
      <BackupWthldComplianceInd>false</BackupWthldComplianceInd>
      <EmployeeCnt>0</EmployeeCnt>
      <UnrelatedBusIncmOverLimitInd>false</UnrelatedBusIncmOverLimitInd>
      <ForeignFinancialAccountInd>false</ForeignFinancialAccountInd>
      <ProhibitedTaxShelterTransInd>false</ProhibitedTaxShelterTransInd>
      <TaxablePartyNotificationInd>false</TaxablePartyNotificationInd>
      <NondeductibleContributionsInd>false</NondeductibleContributionsInd>
      <IndoorTanningServicesInd>false</IndoorTanningServicesInd>
      <SubjToTaxRmnrtnExPrchtPymtInd>false</SubjToTaxRmnrtnExPrchtPymtInd>
      <SubjectToExcsTaxNetInvstIncInd>false</SubjectToExcsTaxNetInvstIncInd>
      <InfoInScheduleOPartVIInd>X</InfoInScheduleOPartVIInd>
      <GoverningBodyVotingMembersCnt>6</GoverningBodyVotingMembersCnt>
      <IndependentVotingMemberCnt>6</IndependentVotingMemberCnt>
      <FamilyOrBusinessRlnInd>false</FamilyOrBusinessRlnInd>
      <DelegationOfMgmtDutiesInd>false</DelegationOfMgmtDutiesInd>
      <ChangeToOrgDocumentsInd>false</ChangeToOrgDocumentsInd>
      <MaterialDiversionOrMisuseInd>false</MaterialDiversionOrMisuseInd>
      <MembersOrStockholdersInd>false</MembersOrStockholdersInd>
      <ElectionOfBoardMembersInd>false</ElectionOfBoardMembersInd>
      <DecisionsSubjectToApprovaInd>false</DecisionsSubjectToApprovaInd>
      <MinutesOfGoverningBodyInd>true</MinutesOfGoverningBodyInd>
      <MinutesOfCommitteesInd>true</MinutesOfCommitteesInd>
      <OfficerMailingAddressInd>false</OfficerMailingAddressInd>
      <LocalChaptersInd>false</LocalChaptersInd>
      <Form990ProvidedToGvrnBodyInd>false</Form990ProvidedToGvrnBodyInd>
      <ConflictOfInterestPolicyInd>false</ConflictOfInterestPolicyInd>
      <WhistleblowerPolicyInd>false</WhistleblowerPolicyInd>
      <DocumentRetentionPolicyInd>false</DocumentRetentionPolicyInd>
      <CompensationProcessCEOInd>false</CompensationProcessCEOInd>
      <CompensationProcessOtherInd>false</CompensationProcessOtherInd>
      <InvestmentInJointVentureInd>false</InvestmentInJointVentureInd>
      <BooksInCareOfDetail>
        <PersonNm>CHARLES SERHAN</PersonNm>
        <PhoneNum>3135772999</PhoneNum>
        <USAddress>
          <AddressLine1Txt>5101 CASS AVENUE 431 CHEMISTRY BLD</AddressLine1Txt>
          <CityNm>DETROIT</CityNm>
          <StateAbbreviationCd>MI</StateAbbreviationCd>
          <ZIPCd>48202</ZIPCd>
        </USAddress>
      </BooksInCareOfDetail>
      <NoListedPersonsCompensatedInd>X</NoListedPersonsCompensatedInd>
      <Form990PartVIISectionAGrp>
        <PersonNm>CHARLES SERHAN</PersonNm>
        <TitleTxt>PRESIDENT</TitleTxt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>KRISHNARAO MADDIPATI</PersonNm>
        <TitleTxt>TREASURER</TitleTxt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MAKOTO ARITA</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>EDWARD DENNIS</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>GABOR TIGYI</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>TAKEHIKO YOKOMIZO</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <FormerOfcrEmployeesListedInd>false</FormerOfcrEmployeesListedInd>
      <TotalCompGreaterThan150KInd>false</TotalCompGreaterThan150KInd>
      <CompensationFromOtherSrcsInd>false</CompensationFromOtherSrcsInd>
      <GovernmentGrantsAmt>18956</GovernmentGrantsAmt>
      <TotalContributionsAmt>18956</TotalContributionsAmt>
      <InvestmentIncomeGrp>
        <TotalRevenueColumnAmt>2</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>2</RelatedOrExemptFuncIncomeAmt>
      </InvestmentIncomeGrp>
      <OtherRevenueMiscGrp>
        <Desc>OTHER INCOME</Desc>
        <TotalRevenueColumnAmt>1122</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>1122</RelatedOrExemptFuncIncomeAmt>
      </OtherRevenueMiscGrp>
      <OtherRevenueTotalAmt>1122</OtherRevenueTotalAmt>
      <TotalRevenueGrp>
        <TotalRevenueColumnAmt>20080</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>1124</RelatedOrExemptFuncIncomeAmt>
      </TotalRevenueGrp>
      <FeesForServicesLegalGrp>
        <TotalAmt>7330</TotalAmt>
        <ProgramServicesAmt>7330</ProgramServicesAmt>
      </FeesForServicesLegalGrp>
      <AdvertisingGrp>
        <TotalAmt>1700</TotalAmt>
        <ProgramServicesAmt>1700</ProgramServicesAmt>
      </AdvertisingGrp>
      <OfficeExpensesGrp>
        <TotalAmt>272</TotalAmt>
        <ManagementAndGeneralAmt>272</ManagementAndGeneralAmt>
      </OfficeExpensesGrp>
      <TravelGrp>
        <TotalAmt>8882</TotalAmt>
        <ProgramServicesAmt>8882</ProgramServicesAmt>
      </TravelGrp>
      <ConferencesMeetingsGrp>
        <TotalAmt>258</TotalAmt>
        <ProgramServicesAmt>258</ProgramServicesAmt>
      </ConferencesMeetingsGrp>
      <OtherExpensesGrp>
        <Desc>SPEAKER MEALS</Desc>
        <TotalAmt>3664</TotalAmt>
        <ProgramServicesAmt>3664</ProgramServicesAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>CONTRACTORS</Desc>
        <TotalAmt>2419</TotalAmt>
        <ProgramServicesAmt>2419</ProgramServicesAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>WEBSITE/COMPUTER EXPENSE</Desc>
        <TotalAmt>1083</TotalAmt>
        <ManagementAndGeneralAmt>1083</ManagementAndGeneralAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>POSTER AWARDS</Desc>
        <TotalAmt>600</TotalAmt>
        <ProgramServicesAmt>600</ProgramServicesAmt>
      </OtherExpensesGrp>
      <AllOtherExpensesGrp>
        <TotalAmt>218</TotalAmt>
        <ProgramServicesAmt>198</ProgramServicesAmt>
        <ManagementAndGeneralAmt>20</ManagementAndGeneralAmt>
      </AllOtherExpensesGrp>
      <TotalFunctionalExpensesGrp>
        <TotalAmt>26426</TotalAmt>
        <ProgramServicesAmt>25051</ProgramServicesAmt>
        <ManagementAndGeneralAmt>1375</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </TotalFunctionalExpensesGrp>
      <CashNonInterestBearingGrp>
        <BOYAmt>17889</BOYAmt>
        <EOYAmt>10801</EOYAmt>
      </CashNonInterestBearingGrp>
      <TotalAssetsGrp>
        <BOYAmt>17889</BOYAmt>
        <EOYAmt>10801</EOYAmt>
      </TotalAssetsGrp>
      <AccountsPayableAccrExpnssGrp>
        <EOYAmt>-742</EOYAmt>
      </AccountsPayableAccrExpnssGrp>
      <TotalLiabilitiesGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>-742</EOYAmt>
      </TotalLiabilitiesGrp>
      <OrganizationFollowsFASB117Ind>X</OrganizationFollowsFASB117Ind>
      <NoDonorRestrictionNetAssetsGrp>
        <BOYAmt>17889</BOYAmt>
        <EOYAmt>11543</EOYAmt>
      </NoDonorRestrictionNetAssetsGrp>
      <TotalNetAssetsFundBalanceGrp>
        <BOYAmt>17889</BOYAmt>
        <EOYAmt>11543</EOYAmt>
      </TotalNetAssetsFundBalanceGrp>
      <TotLiabNetAssetsFundBalanceGrp>
        <BOYAmt>17889</BOYAmt>
        <EOYAmt>10801</EOYAmt>
      </TotLiabNetAssetsFundBalanceGrp>
      <InfoInScheduleOPartXIInd>X</InfoInScheduleOPartXIInd>
      <ReconcilationRevenueExpnssAmt>-6346</ReconcilationRevenueExpnssAmt>
      <MethodOfAccountingCashInd>X</MethodOfAccountingCashInd>
      <AccountantCompileOrReviewInd>false</AccountantCompileOrReviewInd>
      <FSAuditedInd>false</FSAuditedInd>
    </IRS990>
    <IRS990ScheduleA documentId="RetDoc3">
      <PubliclySupportedOrg509a2Ind>X</PubliclySupportedOrg509a2Ind>
      <GiftsGrantsContrisRcvd509Grp>
        <CurrentTaxYearMinus4YearsAmt>95299</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>5000</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>72875</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>139190</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>18956</CurrentTaxYearAmt>
        <TotalAmt>331320</TotalAmt>
      </GiftsGrantsContrisRcvd509Grp>
      <GrossReceiptsAdmissionsGrp>
        <CurrentTaxYearMinus4YearsAmt>165715</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>5925</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>126558</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>1124</CurrentTaxYearAmt>
        <TotalAmt>299322</TotalAmt>
      </GrossReceiptsAdmissionsGrp>
      <Total509Grp>
        <CurrentTaxYearMinus4YearsAmt>261014</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>5000</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>78800</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>265748</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>20080</CurrentTaxYearAmt>
        <TotalAmt>630642</TotalAmt>
      </Total509Grp>
      <PublicSupportTotal509Amt>630642</PublicSupportTotal509Amt>
      <GrossInvestmentIncome509Grp>
        <CurrentTaxYearMinus4YearsAmt>17</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>3</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>3</CurrentTaxYearMinus2YearsAmt>
        <TotalAmt>23</TotalAmt>
      </GrossInvestmentIncome509Grp>
      <InvestmentIncomeAndUBTIGrp>
        <CurrentTaxYearMinus4YearsAmt>17</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>3</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>3</CurrentTaxYearMinus2YearsAmt>
        <TotalAmt>23</TotalAmt>
      </InvestmentIncomeAndUBTIGrp>
      <TotalSupportCalendarYearGrp>
        <CurrentTaxYearMinus4YearsAmt>261031</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>5003</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>78803</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>265748</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>20080</CurrentTaxYearAmt>
        <TotalAmt>630665</TotalAmt>
      </TotalSupportCalendarYearGrp>
      <PublicSupportCY509Pct>1.00000</PublicSupportCY509Pct>
      <PublicSupportPY509Pct>0.99990</PublicSupportPY509Pct>
      <InvestmentIncomeCYPct>0.00000</InvestmentIncomeCYPct>
      <InvestmentIncomePYPct>0.00000</InvestmentIncomePYPct>
      <ThirtyThrPctSuprtTestsCY509Ind>X</ThirtyThrPctSuprtTestsCY509Ind>
    </IRS990ScheduleA>
    <IRS990ScheduleO documentId="RetDoc2">
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990 - ORGANIZATION'S MISSION</FormAndLineReferenceDesc>
        <ExplanationTxt>THE PRIMARY EXEMPT PURPOSE OF THE EICOSANOID RESEARCH FOUNDATION IS TO PROVIDE A FORUM FOR THE DISSEMINATION OF THE LATEST SCIENTIFIC INFORMATION ON BIOACTIVE LIPIDS IN HEALTH AND DISEASE AS IT RELATES TO CANCER, INFLAMATION AND INFLAMATION INDUCED DISEASES SUCH AS CARDIOVASCULAR, DIABETES, PSORIASIS AND ALZHEIMER'S. THIS PURPOSE IS ACCOMPLISHED THROUGH THE ORGANIZATION'S BIENNIAL CONFERENCE. THE EICOSANOID RESEARCH FOUNDATION SPONSORS BIENNIAL CONFERENCES HIGHLIGHTING DATA AT THE CUTTING EDGE OF MEDICAL SCIENCE. DURING THESE CONFERENCES NEW DRUGS AND MEDICATIONS ARE DISCUSSED, DATA ON CLINICAL TRIALS IS EXAMINED AND SCIENTISTS FROM ALL OVER THE WORLD INTERACT TO ENHANCE THEIR COLLABORATIVE RESEARCH EFFORTS. THE GOAL OF THIS MEETING SERIES IS TO PROMOTE THE EXCHANGE OF INFORMATION AND IDEAS AMONG INTERNATIONAL SCIENTISTS OF DIVERSE BACKGROUNDS. THE MAIN PURPOSE OF THE EICOSANOID RESEARCH FOUNDATION IS TO RAISE FUNDS TO SPONSOR THE INTERNATIONAL CONFERENCE ON BIOACTIVE LIPIDS IN CANCER, INFLAMMATION AND RELATED DISEASES THEREBY PROMOTING ADVANCES IN THIS AREA OF SCIENCE AND MEDICAL RESEARCH. THE FOUNDATION ALSO ORGANIZES, SUPPORTS AND HOSTS THE ANNUAL WAYNE STATE UNIVERSITY LIPIDS SYMPOSIUM. THE SYMPOSIUM ADDRESSES THE VITAL ROLES OF LIPIDS IN CELLULAR PROCESSES REQUIRED FOR NORMAL PHYSIOLOGICAL FUNCTION.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PAGE 6, PART VI, LINE 11B</FormAndLineReferenceDesc>
        <ExplanationTxt>NO REVIEW WAS OR WILL BE CONDUCTED</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PAGE 6, PART VI, LINE 12C</FormAndLineReferenceDesc>
        <ExplanationTxt>ANNUAL COMPLETION OF CONFLICT OF INTEREST AND COMMITMENT DISCLOSURE FORM</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PAGE 6, PART VI, LINE 19</FormAndLineReferenceDesc>
        <ExplanationTxt>NO OTHER DOCUMENTS AVAILABLE TO THE PUBLIC</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART XI, LINE 9</FormAndLineReferenceDesc>
        <ExplanationTxt>OPENING BALANCE EQUITY 0</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleO>
  </ReturnData>
</Return>
